Piramal Pharma Limited has announced the successful closure of the US FDA inspection at its manufacturing facility in Lexington, Kentucky. The company received an Establishment Inspection Report (EIR) confirming a classification of VAI (Voluntary Action Indicated). This milestone marks the formal conclusion of the inspection process for the site, which was previously initiated in December 2025, reinforcing the facility’s adherence to global quality and operational standards.
Inspection Outcome
Following a rigorous evaluation, the US FDA has officially issued an Establishment Inspection Report (EIR) for the Piramal Pharma manufacturing site located in Lexington, USA. The agency has classified the facility’s status as VAI (Voluntary Action Indicated). This designation signifies that the inspection process has reached a successful conclusion, affirming the company’s commitment to maintaining regulatory compliance.
Strategic Context
The facility was subject to an inspection, with the initial intimation regarding the review provided on December 11, 2025. The receipt of the EIR on April 13, 2026, provides regulatory clarity for the Lexington plant, which plays a vital role in the company’s global manufacturing footprint. This positive outcome is expected to support the continued operational stability and market readiness of the facility.
Source: BSE
